At a median follow-up of ~16 months post-discontinuation, just 4/23 patients had relapsed! 1-year PFS: 84%!

Our NEW Primer on Developmental and epileptic encephalopathies is live today! By Prof Ingrid Scheffer , Sameer M Zuberi , Dr. Heather Mefford, Renzo Guerrini and May McTague. Check it out here: go.nature.com/3TgZ0ck

A short🧵on FISH in AL #Amyloidosis and findings of our multicenter study on 283 patients with AL treated with daratumumab-based frontline therapy (Dara-VCd/Dara-Vd) Blood Journal ashpublications.org/blood/article-…

The right way to approach conferences in Australia 😋

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review The Oncologist #mmsm ➡️academic.oup.com/oncolo/article… Responses to similar treatments are usually lower in smoldering myeloma compared to multiple myeloma👇

Congrats Professor Kaiser!!

This article reviews clinical trials of smoldering multiple myeloma, comparing efficacy of treatment regimens in smoldering multiple myeloma to results from these regimens when used in newly diagnosed multiple myeloma. doi.org/10.1093/oncolo… #myeloma #BloodCancerAwareness

📣 Major milestone reached: 10,000 CAR-T treated #patients registered in the #EBMT Registry! 🙌 📈 This achievement highlights the incredible progress and growing impact of chimeric antigen receptor T-cell (CAR-T) therapy in treating haematological malignancies. 🔬 We are very

The worsening mpox outbreak in Africa: a call to action - The Lancet Infectious Diseases thelancet.com/journals/lanin…

#Myeloma Paper of the Day: Systematic review & meta-analysis of 5,517 lymphoma & myeloma patients post-CAR T finds overall SPM point estimate of 5.8%, but no differences in randomized studies vs. control arms (p=0.92): pubmed.ncbi.nlm.nih.gov/39256908/. #mmsm

Will be interesting to see which recommendations the government chooses to implement and how quickly Good to see emphasis on trying to increase access & speed of access Mark Butler MP Dr Monique Ryan MP

How are public and private insurers thinking about paying for new cell & gene therapies? This Friday, our expert panel will unpack the current landscape and options for increasing access to these treatments while creating sustainable payment strategies. ldi.upenn.edu/events/coverin…

Excited to share our new paper focusing on Second Primary Malignancies (SPMs) following CAR T-cell therapy out today in Clinical Cancer Research ! 👇 This first-in-kind meta-analysis spans 5,517 lymphoma and myeloma patients receiving a range of CAR-T products. aacrjournals.org/clincancerres/…

Mega CAR T meta-analysis "Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients" Bottom line: - frequency of SPMs w CAR-T is not increased compared to SOC strategies -SPM occurrence after CAR T is

Great talk by Dr. Falchi (MSK) at the T cell immunotherapy meeting in Bologna - starting to unravel resistance mechanisms to bispecific antibodies and designing trials to address them medrxiv.org/content/10.110…

AutoSCT vs alloSCT in CR1 for PTCL Long term f/up of AATT RCT Journal of Clinical Oncology 7 yr EFS: allo 38% v auto 34% 7 yr OS: allo 55% v auto 61% 15/30 pts w early PD, 11/20 pts w post-auto PD had allo. 7 yr OS post salvage allo 61%, NRM 23% ascopubs.org/doi/10.1200/JC… Allo the goal in fit PTCL

Can anyone explain why we continue to see RCTs in mCRPC with ARPI-switch as the control arm? How is the discussion with the patient when offering to participate in trials with this comparator?

This is well worth a read, I've done so twice so far, if interested in Bayesian statistics for research and clinical trials. Very clearly written. thelancet.com/journals/lance…

Old but still timely. Which is unfortunate. ascopubs.org/doi/10.1200/JC…

I found the poster aisle discussing costs of new therapies at #ESMO24